Literature DB >> 3555331

Acyclovir prophylaxis for herpes simplex virus infection.

D Gold, L Corey.   

Abstract

ACV is an effective agent for the treatment and prophylaxis of HSV infections in both IC and immunologically normal individuals. The drug is well tolerated in both populations and is not significantly associated with clinical or laboratory toxicities. Because of the great potential benefit and low risk, organ transplant recipients and patients with hematologic malignancies undergoing induction chemotherapy should be screened routinely for HSV antibodies; seropositive individuals should receive prophylactic ACV during the period of most profound immunosuppression. Immunologically normal individuals with frequently recurring genital HSV or serious complications associated with outbreaks are candidates for long-term suppression with ACV.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3555331      PMCID: PMC174733          DOI: 10.1128/AAC.31.3.361

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  63 in total

1.  Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study.

Authors:  A M Halsos; O P Salo; A Lassus; E A Tjøtta; T Hovi; B O Gabrielsen; A P Fiddian
Journal:  Acta Derm Venereol       Date:  1985       Impact factor: 4.437

2.  Post-herpetic erythema multiforme prevented with prophylactic oral acyclovir.

Authors:  J A Green; S L Spruance; G Wenerstrom; M W Piepkorn
Journal:  Ann Intern Med       Date:  1985-05       Impact factor: 25.391

3.  Acyclovir and suppression of frequently recurring herpetic whitlow.

Authors:  O L Laskin
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

4.  Reactivation of type 2 herpes simplex virus by thoracolumbar neurosurgery.

Authors:  H W Haverkos; G J Pazin; M Ho; P B Nelson
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

5.  Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection.

Authors:  G J Mertz; C W Critchlow; J Benedetti; R C Reichman; R Dolin; J Connor; D C Redfield; M C Savoia; D D Richman; D L Tyrrell
Journal:  JAMA       Date:  1984-09-07       Impact factor: 56.272

6.  Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts.

Authors:  G J Mertz; O Schmidt; J L Jourden; M E Guinan; M L Remington; A Fahnlander; C Winter; K K Holmes; L Corey
Journal:  Sex Transm Dis       Date:  1985 Jan-Mar       Impact factor: 2.830

7.  Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients.

Authors:  D H Shepp; B A Newton; P S Dandliker; N Flournoy; J D Meyers
Journal:  Ann Intern Med       Date:  1985-06       Impact factor: 25.391

8.  Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy.

Authors:  R J Whitley; M Levin; N Barton; B J Hershey; G Davis; R E Keeney; J Whelchel; A G Diethelm; P Kartus; S J Soong
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

9.  Infectious complications in heart-lung transplant recipients.

Authors:  R G Brooks; J M Hofflin; S W Jamieson; E B Stinson; J S Remington
Journal:  Am J Med       Date:  1985-10       Impact factor: 4.965

10.  Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.

Authors:  H Anderson; J H Scarffe; R N Sutton; E Hickmott; D Brigden; C Burke
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640

View more
  15 in total

1.  Manzamine A as a novel inhibitor of herpes simplex virus type-1 replication in cultured corneal cells.

Authors:  Jayavardhana R Palem; Gautam R Bedadala; Khalid A El Sayed; Shao-chung V Hsia
Journal:  Planta Med       Date:  2010-07-19       Impact factor: 3.352

2.  Acyclovir prophylaxis for herpes simplex virus infection.

Authors:  L H Goldberg; J Sperber
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

Review 3.  Ocular surgery after herpes simplex and herpes zoster keratitis.

Authors:  Piotr Kanclerz; Jorge L Alio
Journal:  Int Ophthalmol       Date:  2020-09-10       Impact factor: 2.031

4.  The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin.

Authors:  M Halberstadt; M Machens; K-A Gahlenbek; M Böhnke; J G Garweg
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

5.  Oral acyclovir suppression and neurodevelopment after neonatal herpes.

Authors:  David W Kimberlin; Richard J Whitley; Wen Wan; Dwight A Powell; Gregory Storch; Amina Ahmed; April Palmer; Pablo J Sánchez; Richard F Jacobs; John S Bradley; Joan L Robinson; Mark Shelton; Penelope H Dennehy; Charles Leach; Mobeen Rathore; Nazha Abughali; Peter Wright; Lisa M Frenkel; Rebecca C Brady; Russell Van Dyke; Leonard B Weiner; Judith Guzman-Cottrill; Carol A McCarthy; Jill Griffin; Penelope Jester; Misty Parker; Fred D Lakeman; Huichien Kuo; Choo Hyung Lee; Gretchen A Cloud
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

Review 6.  Persistent herpes simplex virus infection and mechanisms of virus drug resistance.

Authors:  H J Field
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

7.  In vitro toxicological evaluation of ISIS 1082, a phosphorothioate oligonucleotide inhibitor of herpes simplex virus.

Authors:  R M Crooke; G D Hoke; J E Shoemaker
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

8.  Herpes simplex virus hepatitis after solid organ transplantation in adults.

Authors:  S Kusne; M Schwartz; M K Breinig; J S Dummer; R E Lee; R Selby; T E Starzl; R L Simmons; M Ho
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

9.  Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis.

Authors:  G Boivin; A Erice; D D Crane; D L Dunn; H H Balfour
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 10.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.